CellGenTech is currently exploring opportunities for alliances to advance the development of gene/cell therapy using Genetically Modified Adipocytes(GMAC). We are now performing the translational clinical research for LCAT deficiency as the 1st target and trying to expand this new therapy to other rare diseases.
"Results of Clinical Trial Using LCAT-GMAC were Published in Heliyon"
The results of a Type 1 regenerative medicine clinical study of LCAT genetically modified human adipocytes (LCAT-GMAC) for the treatment of familial LCAT deficiency, jointly conducted by our company and Chiba University, have been published in Heliyon, a journal of the Cell Press family. The world's first genetically modified human adipocytes GMAC were implanted, and the safety and efficacy of the implanted adipocytes were published. November 2, 2022
Heliyon: Publication site
Adopted for the FY2022 "Fundamental Technology Development Project for the Industrialization of Regenerative Medicine and Gene Therapy (Project to Promote the Industrialization of Regenerative/Cell Medicine and Gene Therapy) (Development Assistance Project)" The Japan Agency for Medical Research and Development (AMED) has selected our company for a development subsidy project. With this support, we will conduct non-clinical studies for clinical trials of
"Factor VIII Gene-Genetically Modified Adipocytes (FVIII-GMAC) for regenerative medicine and gene therapy for hemophilia A". October 4, 2022
CellGenTech Inc. signed a joint development and license agreement with Kyorin Pharmaceutical Co., Ltd. for GMAC of Fabry disease.
June 17, 2022
Toho Holdings Co., Ltd. announced that it will invest in CellGenTech to strengthen its specialty pharmaceutical initiatives, including gene therapy drugs and regenerative medicine products.
December 10, 2021
Nissui Pharmaceutical Co., Ltd. announced that it will invest in CellGenTech in order to accelerate its efforts to develop technologies to support regenerative medicine and to contribute to the practical application of regenerative medicine, utilizing the expertise the company has accumulated over many years in research and development such as (1) technology related to cell culture media for regenerative medicine, (2) technology related to diagnostic reagents and in vitro diagnostic products, and (3) plant for manufacturing culture media for regenerative medicine. October 28, 2021
CellGenTech, Inc. has entered into a licensing agreement with DyDo Pharma, Inc., for commercialization of LCAT-GMAC, a promising novel treatment for familial LCAT deficiency January 15, 2021